AIM ImmunoTech Inc. — Director's Dealing 2017

May 2, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HEMISPHERX BIOPHARMA INC (HEB)
CIK: 0000946644
Period of Report: 2017-05-02

Reporting Person: STRAYER DAVID R (Chief Science/Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-05-02	Common Stock	P	7937	$0.63	Acquired	41804	Direct